A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer.

Sang Eun YoonYoujin KimJangho ChoMinyong KangHyun Hwan SungHwang Gyun JeonByoung Chang JeongSeong Il SeoSeong Soo JeonHyun Moo LeeHan Yong ChoiSu Jin LeeSe Hoon Park

Published in: BMC urology (2019)

ADT plus biweekly-administered docetaxel appeared to be tolerated and effective in patients with high-risk mCNPC.

Keyphrases

prostate cancer
locally advanced
squamous cell carcinoma
radical prostatectomy
small cell lung cancer
radiation therapy